![Page 1: ICARE Member Reports NIH Countermeasures Against Chemical Threats (CounterACT) Program To develop FDA-approved therapeutics and diagnostic technologies](https://reader031.vdocument.in/reader031/viewer/2022020417/56649f385503460f94c54700/html5/thumbnails/1.jpg)
ICARE Member ReportsICARE Member Reports
NIH Countermeasures Against Chemical Threats (CounterACT) Program
To develop FDA-approved therapeutics and diagnostic technologies that will reduced mortality and morbidity during and after chemical emergency events
![Page 2: ICARE Member Reports NIH Countermeasures Against Chemical Threats (CounterACT) Program To develop FDA-approved therapeutics and diagnostic technologies](https://reader031.vdocument.in/reader031/viewer/2022020417/56649f385503460f94c54700/html5/thumbnails/2.jpg)
NERVEAGENT
INHIBITIONOF AChE
RISE INACh
ACTIVATION OFMUSCARINICRECEPTORS
EPILEPTIFORMACTIVITY
NEURONALDAMAGE
PHYSIOLOGICALAND METABOLICEFFECTS
ACTIVATION OFGLUTAMATERECEPTORS
INTRACELLULARACCUMULATIONOF Ca++
Seizure-Pathology Model
Chemical Nerve Agents
Therapeutic Approaches:• Anticholinergics• AChE Reactivators• Anticonvulsants• Neuroprotectants• Single Antidote
![Page 3: ICARE Member Reports NIH Countermeasures Against Chemical Threats (CounterACT) Program To develop FDA-approved therapeutics and diagnostic technologies](https://reader031.vdocument.in/reader031/viewer/2022020417/56649f385503460f94c54700/html5/thumbnails/3.jpg)
LD50 of VX
![Page 4: ICARE Member Reports NIH Countermeasures Against Chemical Threats (CounterACT) Program To develop FDA-approved therapeutics and diagnostic technologies](https://reader031.vdocument.in/reader031/viewer/2022020417/56649f385503460f94c54700/html5/thumbnails/4.jpg)
ICARE Member Reports: ICARE Member Reports: CounterACTCounterACT
Major topics of interest in epilepsy researchAnticonvulsant and Neuroprotectant Research &
DevelopmentEmergency Medical Intervention (Diagnosis & Treatment of
Seizures)Treatment of Refractory and Recurring Seizures
![Page 5: ICARE Member Reports NIH Countermeasures Against Chemical Threats (CounterACT) Program To develop FDA-approved therapeutics and diagnostic technologies](https://reader031.vdocument.in/reader031/viewer/2022020417/56649f385503460f94c54700/html5/thumbnails/5.jpg)
ICARE Member Reports: ICARE Member Reports: CounterACTCounterACT
Types of research support or other activitiesBasic and translational research portfolioCo-funding of RAMPART: a clinical trial on the pre-hospital
use of IM midazolam in an autoinjectorSupport for NINDS Anticonvulsant Screening Program
(CounterACT Tract)Development of a portable, field-deployable EEG device (3
prototypes being tested)
![Page 6: ICARE Member Reports NIH Countermeasures Against Chemical Threats (CounterACT) Program To develop FDA-approved therapeutics and diagnostic technologies](https://reader031.vdocument.in/reader031/viewer/2022020417/56649f385503460f94c54700/html5/thumbnails/6.jpg)
Resources available for shared use or other opportunities for collaborationAnticonvulsant Screening Program – U. UtahCounterACT Preclinical Development Facility (SRI Int. –
Menlo Park, CA)US Army MRICD – Aberdeen, MD (Screening w/ nerve
agents)Battelle Labs - Columbus, OH (GLP Screening w/ nerve
agents)
ICARE Member Reports: ICARE Member Reports: CounterACTCounterACT
![Page 7: ICARE Member Reports NIH Countermeasures Against Chemical Threats (CounterACT) Program To develop FDA-approved therapeutics and diagnostic technologies](https://reader031.vdocument.in/reader031/viewer/2022020417/56649f385503460f94c54700/html5/thumbnails/7.jpg)
Priorities for future activitiesTranslating basic discoveries made during first 5 years to
clinicNext generation anticonvulsants and neuroprotectantsCast a wide net to capture potential lead compoundsRepositioning FDA-approved drugs
ICARE Member Reports: ICARE Member Reports: CounterACTCounterACT